Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Baxter
Harvard Business School
Dow
Medtronic

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

RITUXAN HYCELA Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for RITUXAN HYCELA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Emory UniversityPhase 2
Genentech, Inc.Phase 2
Acerta Pharma BVPhase 1

See all RITUXAN HYCELA clinical trials

Recent Litigation for RITUXAN HYCELA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all RITUXAN HYCELA litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all RITUXAN HYCELA litigation

Patent Text Search: US Patents for RITUXAN HYCELA

These patents were identified by searching patent claims

Supplementary Protection Certificates for RITUXAN HYCELA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122017000101 Germany   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
300822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
C201730059 Spain   Start Trial PRODUCT NAME: INOTUZUMAB OZOGAMICINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1200; DATE OF AUTHORISATION: 20170629; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1200; DATE OF FIRST AUTHORISATION IN EEA: 20170629
CR 2017 00053 Denmark   Start Trial PRODUCT NAME: ANTISTOF-LAEGEMIDDEL-KONJUGAT, HVORI ET CD22-RETTET ANTISTOF ER KOVALENT BUNDET TIL N-ACETYL-GAMMA-CALICHEAMICIN DIMETHYLHYDRAZID, SVARENDE TIL INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170703
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
McKesson
Colorcon
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.